G2GBIO Inc
456160
Company Profile
Business description
G2GBIO Inc is a Biotechnology company. The company manages Drug Delivery System platform company. The company possesses microsphere source technology (InnoLAMP) for the development of sustained-release pharmaceuticals, and development a demand for extended-half-life drugs, as well as world-class mass production processes and facilities.
Contact
21 Medical Complex-gil
Osong-eup
Heungdeok-gu
Chungcheongbuk-do
Cheongju-si
KORT: +82 432706000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
48
Stocks News & Analysis
stocks
Wide moat stock exchange remains cheap
Aussie stock exchange remains materially undervalued despite growing cost concerns.
stocks
ASX data center player expands pipeline but questions remain
Questions surround Australia’s largest data center developer and its growing pipeline.
stocks
Cheap e-commerce share continues sales momentum
The e-commerce business continues its sales momentum despite challenging backdrop.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,965.00 | 77.80 | 0.88% |
| CAC 40 | 8,204.73 | 15.86 | 0.19% |
| DAX 40 | 25,065.21 | 27.04 | -0.11% |
| Dow JONES (US) | 50,889.54 | 220.57 | 0.44% |
| FTSE 100 | 10,417.48 | 8.48 | -0.08% |
| HKSE | 25,182.39 | 176.23 | 0.70% |
| NASDAQ | 27,013.79 | 96.32 | 0.36% |
| Nikkei 225 | 66,329.50 | 1,636.38 | 2.53% |
| NZX 50 Index | 13,244.55 | 38.44 | 0.29% |
| S&P 500 | 7,590.12 | 26.49 | 0.35% |
| S&P/ASX 200 | 8,731.70 | 73.10 | 0.84% |
| SSE Composite Index | 4,068.57 | 30.07 | -0.73% |